ReviewJournal of clinical medicine2022
The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review.Inflammatory bowel diseases · 2025Pooled it
- Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.Journal of gastroenterology · 2026Article
- Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease.The American journal of gastroenterology · 2026Review
- Extensive trans-organ urogenital fistulation in Crohn's disease involving the bowel, urinary bladder, seminal vesicles, and prostate: Radiological perspective of a case.Radiology case reports · 2026Article
- Safety and feasibility of the bowel-first versus conventional approach in intra-abdominal penetrating Crohn's disease: a propensity score-matched study.BMC surgery · 2025Article
- Effectiveness and Safety of Advanced Dual-Targeted Therapy in Refractory Perianal Crohn's Disease.United European gastroenterology journal · 2025Article
- Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease.Journal of clinical medicine · 2025Article
- Long-term effectiveness of allogeneic bone marrow-derived mesenchymal stromal cell therapy for complex perianal and rectovaginal fistulas in Crohn's disease: a retrospective case series.BMJ open gastroenterology · 2025Article
- Article
- Gastrointestinal Fistulas-What Gastroenterologists Need to Know in 2025.Canadian journal of gastroenterology & hepatology · 2025Review
- Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian Cohort.Gastro hep advances · 2025Article
- Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.BMC gastroenterology · 2024Article
- Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab.Advances in therapy · 2024Article
- Article
- Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn's disease: A cohort study from northern India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- A complex presentation and successful management of fistulizing perianal Crohn's disease extending to the mid-back.Journal of surgical case reports · 2023Article
- The Intersection of Human and Veterinary Medicine-A Possible Direction towards the Improvement of Cell Therapy Protocols in the Treatment of Perianal Fistulas.International journal of molecular sciences · 2022Review
- Is surgery necessary for colonic fistulas and psoas abscesses in patients with Crohn's disease? A case report.International journal of surgery case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fistulizing Crohn's disease (FCD) remains the most challenging aspect of treating patients with CD. FCD can occur in up to 30% of patients with CD and may lead to significant disability and impaired quality of life. The optimal treatment strategies for FCD require a multidisciplinary approach, including a combined medical and surgical approach. The therapeutic options for FCD are limited due to sparse evidence from randomized clinical trials (RCTs). The current recommendations are mainly based on post hoc analysis from RCTs, real-world clinical studies and expert opinion. There is variation in everyday clinical practice amongst gastroenterologists and surgeons. The evidence for anti-tumor necrosis factor therapy is the strongest in the treatment of FCD. However, long-term fistula healing can be achieved in only 30-50% of patients. In recent years, emerging data in the advent of therapeutic modalities, including the use of new biologic agents, therapeutic drug monitoring, novel surgical methods and mesenchymal stem cell therapy, have been shown to improve outcomes in achieving fistula healing. This review summarizes the existing literature on current and emerging therapies to provide guidance beyond RCTs in managing FCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.